论文部分内容阅读
The occurrence of highly pathogenic avian influenza virus H5N1 highlights the urgent need for new classes of antiviral drugs.Theoretically,each of steps in influenza viral life cycle can be a target of antiviral therapeutics.However,up to date,no licenced entry inhibitor drug is available for H5N1 or any other influenza viruses.